Aquestive Therapeutics (AQST) is expected to report fourth-quarter and full-year 2023 results later this month or early next month. In the last reported quarter, the company beat earnings expectations by 72.73%. Factors to Consider Aquestive earns royalty revenues from its five out-licensed marketed products that it supplies under license deals with partners. Aquestive is the exclusive manufacturer of these licensed products. Its revenues from these products are expected to have increased in the fourth quar ...